Novo Nordisk Shares Drop as Earnings Miss, Guidance Cut Amid Obesity Drug Competition
Mondeum Capital (UK) Limited
Novo Nordisk A/S shares slid Thursday after the Danish drugmaker reported quarterly earnings that missed analyst estimates and lowered its full-year outlook, fueling investor anxiety over slowing growth in its blockbuster obesity franchise.
The company posted third-quarter earnings of 4.50 kroner per share, falling short of analysts’ expectations of 4.90 kroner, according to data compiled by FactSet. Novo also trimmed its annual sales guidance, citing moderating demand for Wegovy, its weight-loss injection that has driven the company’s meteoric rise over the past two years.
The softer outlook comes as Eli Lilly & Co. intensifies competition in the obesity drug market with its rival treatment Zepbound, which has quickly gained traction in the U.S. Novo’s dominance in the fast-growing sector is also being tested by supply constraints and increasing pricing scrutiny from regulators and insurers.
Adding to market unease, Novo is undergoing a period of transition marked by executive changes and planned layoffs, part of a broader restructuring to refocus resources on obesity and diabetes treatments.
In a sign of its continued ambition in the space, the company recently entered a bidding war with Pfizer Inc. for Metsera, a privately held biotech specializing in obesity therapies. Novo’s Chief Financial Officer defended the offer—both in value and structure—amid legal challenges from Pfizer, which has accused Novo of anticompetitive behavior.
Despite investor concerns, Novo executives said the revised guidance reflects a “prudent recalibration” of expectations as the company invests heavily in capacity expansion and next-generation obesity drugs.
Shares of Novo Nordisk were down in Copenhagen trading, extending a recent pullback that has erased part of the company’s market-value gains from earlier this year.
The moves underscore the increasingly competitive landscape for obesity and diabetes treatments—markets once dominated by Novo but now drawing deep-pocketed rivals and heightened regulatory scrutiny.
Featured CoursesRecent news
ServiceNow and Software Stocks Lead Sector Recovery on AI Hopes
Software stocks are making a comeback. ServiceNow jumped 8.8% on Monday, marking its largest one-day gain in over a year. This surge followed BofA Securities reinstating coverage with a Buy rating, which helped restore investor confidence in a sector that faced pressure in 2026 over concerns that AI might replace, not support, enterprise software. Here’s […]
GE Aerospace Stock Rises as AI Cuts Hypersonic Engine Design Time
GE Aerospace is showing investors what artificial intelligence looks like when applied to one of the world’s most technically demanding industries. Shares rose 1.58% Tuesday as the company revealed that researchers at its Niskayuna, New York, facility used an in-house generative AI tool to produce a preliminary hypersonic ramjet engine design, compressing a process that […]
Nvidia Shares Slip 1.1%: Why a 3-Day Losing Streak Could Be Good News
Nvidia is heading into its most anticipated earnings report of the year on the back foot, and that may be exactly what the stock needs. Shares fell 1.1% in premarket trading Tuesday, extending a three-day pullback from last Thursday’s closing high of $235.74. For investors watching closely, a lower entry point ahead of Wednesday’s results […]
Trade with fewer limits
Day trade with fewer limits at fast speed. Buy stocks and ETFs at low fees.